![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
AJ Stewart, C Pichon, L Meunier, P Midoux, M Monsigny and AC Roche
Glycobiologie, Orleans, France.
We sought to exploit glycosylated poly-L-lysine (pLK) to increase the uptake and biological antisense activity of a phosphorothioate oligonucleotide (pt-odn) [pt-odn complementary to the 3' noncoding region of intercellular adhesion molecule-1 (ICAM-1) (odn(ICAM-1))] complementary to the 3'-noncoding region of ICAM-1 in A549 cells. Dose- dependent inhibition of ICAM-1 expression was obtained (IC50 = 500 nM) through treatment of cells with odn(ICAM-1) complexed with pLK carrying fucose residues in the presence of 100 microM chloroquine. Alteration in the charge ratio between fucosylated pLK and pt-odn had a significant effect on the efficacy of inhibition (optimal conditions, charge ratio = 1.1). This effect was also dependent on the number of fucose moieties per pLK. Free pt-odn or pt-odn complexed with nonglycosylated pLK gave no inhibition at concentrations of < or = 2 microM. Two control pt-odn (one was targeted against an unrelated gene not present in these cells, gag(HIV), and the other had a randomized sequence) gave no inhibition of ICAM-1 expression in the presence or absence of pLK carrying fucose residues at concentrations of < or = 2 microM. When complexed with pLK carrying 100 fucose residues, the amount of cell-associated pt-odn was increased by 15-fold compared with the free pt-odn. Nongycosylated pLK also increased the amount of cell- associated pt-odn by >10 fold but did not alter the biological activity. These results demonstrate clearly the potential of glycosylated pLK as a pt-odn transporter.
This article has been cited by other articles:
|
|
 |
|
  J. J. Turner, G. D. Ivanova, B. Verbeure, D. Williams, A. A. Arzumanov, S. Abes, B. Lebleu, and M. J. Gait Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells Nucleic Acids Res., November 30, 2005; 33(21): 6837 - 6849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dias and C. A. Stein Antisense Oligonucleotides: Basic Concepts and Mechanisms Mol. Cancer Ther., March 1, 2002; 1(5): 347 - 355. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Q. Sun, M. J. Cairns, E. G. Saravolac, A. Baker, and W. L. Gerlach Catalytic Nucleic Acids: From Lab to Applications Pharmacol. Rev., September 1, 2000; 52(3): 325 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pichon, M. B. Roufai, M. Monsigny, and P. Midoux Histidylated oligolysines increase the transmembrane passage and the biological activity of antisense oligonucleotides Nucleic Acids Res., January 15, 2000; 28(2): 504 - 512. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
